Corcept Therapeutics Incorporated (LON: 0I3Q)
London
· Delayed Price · Currency is GBP · Price in USD
58.22
+1.97 (3.50%)
Jan 22, 2025, 7:04 PM BST
Corcept Therapeutics Revenue
Corcept Therapeutics had revenue of $182.55M USD in the quarter ending September 30, 2024, with 47.69% growth. This brings the company's revenue in the last twelve months to $628.56M, up 39.67% year-over-year. In the year 2023, Corcept Therapeutics had annual revenue of $482.38M with 20.04% growth.
Revenue (ttm)
$628.56M
Revenue Growth
+39.67%
P/S Ratio
n/a
Revenue / Employee
$1.79M
Employees
352
Market Cap
5.02B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 482.38M | 80.52M | 20.04% |
Dec 31, 2022 | 401.86M | 35.88M | 9.80% |
Dec 31, 2021 | 365.98M | 12.10M | 3.42% |
Dec 31, 2020 | 353.87M | 47.39M | 15.46% |
Dec 31, 2019 | 306.49M | 55.24M | 21.99% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Corcept Therapeutics News
- 23 days ago - Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism - Business Wire
- 5 weeks ago - Corcept Therapeutics Inc (CORT) Announces Promising Phase 3 Study Results for Relacorilant - GuruFocus
- 5 weeks ago - Corcept's Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism - Business Wire
- 5 weeks ago - Corcept Therapeutics Inc (CORT) Announces Positive Results from CATALYST Study - GuruFocus
- 5 weeks ago - Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control Diabetes - Benzinga
- 5 weeks ago - Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control Diabetes - Business Wire
- 6 weeks ago - Corcept Therapeutics' ALS drug fails in mid-stage trial - Reuters
- 6 weeks ago - Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) - Business Wire